Loading... Please wait... Loading... Please wait...
ESTIMATED
05/10/2024
05/10/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.98 | -$0.98 | -$0.98 |
| Q2 2024 | 4 | -$1.15 | -$0.80 | -$1.04 |
| Q3 2024 | 1 | -$1.05 | -$1.05 | -$1.05 |
| Q4 2024 | 1 | -$1.11 | -$1.11 | -$1.11 |
| Q1 2025 | 2 | -$1.35 | -$1.35 | -$1.35 |
| Q2 2025 | 2 | -$1.47 | -$1.47 | -$1.47 |
| Q3 2025 | 2 | -$1.43 | -$1.43 | -$1.43 |
| Q4 2025 | 2 | -$1.54 | -$1.54 | -$1.54 |
| Q1 2026 | 1 | -$1.83 | -$1.83 | -$1.83 |
| Q2 2026 | 1 | -$1.76 | -$1.76 | -$1.76 |
| Q3 2026 | 1 | -$1.78 | -$1.78 | -$1.78 |
| Q4 2026 | 1 | -$1.80 | -$1.80 | -$1.80 |
| Q1 2027 | 1 | -$1.81 | -$1.81 | -$1.81 |
| Q2 2027 | 1 | -$1.58 | -$1.58 | -$1.58 |
| Q3 2027 | 1 | -$1.42 | -$1.42 | -$1.42 |
| Q4 2027 | 1 | -$1.21 | -$1.21 | -$1.21 |
iTeos Therapeutics, Inc. last posted its earnings results on Friday, May 10th, 2024. The company reported $-1.07 earnings per share for the quarter, missing analysts' consensus estimates of $-1.02 by $0.05. The company had revenue of 0 for the quarter and had revenue of 12.60 M for the year. iTeos Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-3.15 diluted earnings per share) and currently has a price-to-earnings ratio of -3.92. iTeos Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/10/2024 | Q1 2024 | -$1.02 | -$1.07 | -0.05 | $0 | $0 | 03/06/2024 | Q4 2023 | -$1.03 | -$0.85 | 0.18 | $12.47 M | $-11,303,000 | 11/07/2023 | Q3 2023 | -$1.20 | -$0.90 | 0.3 | $0 | 08/08/2023 | Q2 2023 | -$1.03 | -$0.96 | 0.07 | $0 | 05/10/2023 | Q1 2023 | -$0.99 | -$0.44 | 0.55 | $6.90 M | $12.60 M | 03/15/2023 | Q4 2022 | $0.42 | $0.57 | 0.15 | $41.16 M | $53.91 M | 11/10/2022 | Q3 2022 | $0.10 | $0.03 | -0.07 | $19.49 M | 08/10/2022 | Q2 2022 | $1.20 | $0.15 | -1.05 | $41.72 M | 05/12/2022 | Q1 2022 | $0.80 | $1.82 | 1.02 | $152.52 M | 03/23/2022 | Q4 2021 | $1.29 | -$0.84 | -2.13 | $85.45 M | $240.50 M | 11/10/2021 | Q3 2021 | $4.95 | $1.98 | -2.97 | $6.50 M | $104.27 M | 08/11/2021 | Q2 2021 | -$0.75 | $3.91 M | $0 | 05/13/2021 | Q1 2021 | -$0.48 | -$0.39 | 0.09 | $0 | 03/24/2021 | Q4 2020 | -$0.42 | -$0.61 | -0.19 | $0 | 11/12/2020 | Q3 2020 | -$0.36 | -$0.44 | -0.08 | $0 | 09/01/2020 | Q2 2020 | -$0.47 | -$0.23 | 0.24 | $0 | 03/30/2020 | Q1 2020 | -$0.17 | $0 | 12/30/2019 | Q4 2019 | -$0.54 | $0 | 09/29/2019 | Q3 2019 | -$0.70 | $0 | 06/29/2019 | Q2 2019 | -$0.58 | $0 |
|---|
A. iTeos Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off last year's report dates.
A. The conference call for iTeos Therapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for iTeos Therapeutics, Inc.'s latest earnings report can be read online.
A. iTeos Therapeutics, Inc. (NASDAQ:ITOS) has a recorded annual revenue of $12.60 M.
A. iTeos Therapeutics, Inc. (NASDAQ:ITOS) has a recorded net income of $12.60 M. iTeos Therapeutics, Inc. has generated $-3.15 earnings per share over the last four quarters.
A. iTeos Therapeutics, Inc. (NASDAQ:ITOS) has a price-to-earnings ratio of -3.92 and price/earnings-to-growth ratio is 0.02.
